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Dear editor
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide, 1 with the majority of patients presenting with advanced disease.
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Treg cells diminish the activation and function of lymphocytes via cell-cell contact and secretion of soluble mediators. 3 PD-1 is expressed on the surface of activated T and B cells and regulates their activation and proliferation. 4 PD-L1 binds to the PD-1 receptor, leading to, among other responses, negative regulation of immune activity. Both Tregs and the PD-1/PD-L1 pathway play important roles in lung cancer pathogenesis; 5, 6 however, the association between these two factors remains poorly understood. Here, we examined PD-1 expression on Tregs, and compared these results with established clinical indicators of lung cancer. These analyses revealed significant expression of PD-1 on Tregs in lung cancer, which may be used to inform clinical diagnoses.
PD-1 expression was studied on CD4 + CD25 + CD127 low Tregs isolated from peripheral blood mononuclear cells by flow cytometry. Twenty-two primary lung cancer patients and 25 healthy volunteers were recruited from the Second Affiliated Hospital of Soochow University (Suzhou, People's Republic of China). Lung cancer patients had a nearly 2-fold increase in the number of circulating Tregs relative to healthy controls (7.66%±2.25% versus [vs] 3.76%±1.06%, respectively; P,0.05). The levels of PD-1 expression by CD4
low Tregs were also higher in lung cancer samples compared to controls (46.01%±11.33% vs 33.34%±13.54%, respectively). Significant differences in both CD4
low Treg abundance (6.29%±1.18% vs 10.06%±1.58%; P,0.01) and Treg PD-1 expression (41.85%±6.1% vs 56.57%±12.52%; P,0.05) were observed between clinical stages III and IV, respectively ( Figure 1 ); no differences were seen among other pathologic subtypes, or in terms of lymphatic metastasis.
Tregs play a critical role in a variety of immunologic processes, including selftolerance, anti-tumor immune responses, and transplantation. 7, 8 Our study revealed a significant increase in the number of CD4
low Tregs in patients with lung cancer, relative to healthy controls. While the mechanisms underlying the increase in lung cancer-associated Tregs are not known, the overall increase in the number of immunosuppressive immune cells present in these patients may play an important role in both the development and progression of lung cancer. 9, 10 Costimulatory molecule receptors interacting with their corresponding ligand mediate both positive and negative costimulatory signals, which regulate immune 
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Zhong et al cell activation, including the activation and proliferation of T cells, cytokine production, apoptosis, cell survival, and cytotoxicity.
11-13 PD-1 belongs to the CD28 family of receptors, and is expressed on activated T, B, and myeloid cells. 4 PD-1 and its ligand PD-L1 deliver inhibitory signals that regulate the balance between effector T cell activation and immune-mediated tissue damage. 11, 12 In addition, the proliferation and immune inhibitory activity of Tregs is directly related to the expression of costimulatory molecules on the cell surface.
14 Conflicting reports on the role of PD-1 on Treg function have suggested that PD-1-PD-L1 ligation on Tregs promotes Treg stability and expansion, [15] [16] [17] [18] while others have suggested that this pathway inhibits Treg expansion and function. 19, 20 Our study revealed a distinct increase in Treg number and Treg PD-1 expression in patients with lung cancer, suggesting that the PD-1/PD-L1 pathway may play a role in Treg induction and is associated with impaired adaptive immunity. From these results, we hypothesize that the over-expression of PD-1 on Tregs and/or the increase in Treg number may participate in the immune inhibitory state of lung cancer patients. The cross-talk between Treg cells and PD-1/PD-L1-induced inhibition in lung cancer warrants further exploration for lung cancer associated immune pathogenesis. 
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